The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Kim, Min Kyoung ^a   Jeon, Yoon Kyung ^a   Woo, Jong Kyu ^a   Choi, Yun ^a   Choi, Dae Han ^a   Kim, Yeul Hong ^b   Kim, Chul Woo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Bfl 1; Gemcitabine; Gene therapy; NF B; Non small cell lung cancer

Indexed keywords

ADENOVIRUS VECTOR; BCL2 RELATED PROTEIN A1; COMPLEMENTARY DNA; CYTOCHROME C; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; BCL2-RELATED PROTEIN A1; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CELL VIABILITY; CONTROLLED STUDY; ENZYME RELEASE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR XENOGRAFT; VIRUS RECOMBINANT; ANIMAL; CELL STRAIN HEK293; CHEMISTRY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DEOXYCYTIDINE; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NF-KAPPA B; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051626450     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-98     Document Type: Article

References (48)

1. Cascone T, Gridelli C, Ciardiello F. Combined targeted therapies in non-small cell lung cancer: a winner strategy?. Curr Opin Oncol 2007, 19:98-102. 10.1097/CCO.0b013e328011beec, 17272980.
2. Marx G, Harper P. Non-platinum gemcitabine combinations in non-small cell lung cancer. Lung Cancer 2002, 38(Suppl 2):S51-54.
3. Crino L, Cappuzzo F. Gemcitabine in non-small cell lung cancer. Expert Opin Pharmacother 2002, 3:745-753. 10.1517/14656566.3.6.745, 12036414.
4. Scagliotti GV, Novello S. Gemcitabine (Gemzar)-based induction chemotherapy in non-small-cell lung cancer. Lung Cancer 2002, 38(Suppl 2):S13-19.
5. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, Schafer H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003, 22:3243-3251. 10.1038/sj.onc.1206390, 12761494.
6. Hernandez-Vargas H, Rodriguez-Pinilla SM, Julian-Tendero M, Sanchez-Rovira P, Cuevas C, Anton A, Rios MJ, Palacios J, Moreno-Bueno G. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 2007, 102:157-172. 10.1007/s10549-006-9322-9, 17039268.
7. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002, 5:19-33. 10.1016/S1368-7646(02)00002-X, 12127861.
8. Okamoto K, Ocker M, Neureiter D, Dietze O, Zopf S, Hahn EG, Herold C. bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med 2007, 11:349-361. 10.1111/j.1582-4934.2007.00013.x, 17378914.
9. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004, 95:753-757. 10.1111/j.1349-7006.2004.tb03257.x, 15471562.
10. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64:3761-3766. 10.1158/0008-5472.CAN-03-3363, 15172981.
11. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, van den Ijssel P, Ylstra B, Peters GJ. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005, 65:9510-9516. 10.1158/0008-5472.CAN-05-0989, 16230416.
12. Dumontet C, Bauchu EC, Fabianowska K, Lepoivre M, Wyczechowska D, Bodin F, Rolland MO. Common resistance mechanisms to nucleoside analogues in variants of the human erythroleukemic line K562. Adv Exp Med Biol 1999, 457:571-577.
13. Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, Dumontet C. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 2004, 4:8. 10.1186/1471-2210-4-8, 428575, 15157282.
14. Guchelaar HJ, Vermes A, Vermes I, Haanen C. Apoptosis: molecular mechanisms and implications for cancer chemotherapy. Pharm World Sci 1997, 19:119-125. 10.1023/A:1008654316572, 9259027.
15. Wang CY, Cusack JC, Liu R, Baldwin AS. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999, 5:412-417. 10.1038/7410, 10202930.
16. Jones DR, Broad RM, Comeau LD, Parsons SJ, Mayo MW. Inhibition of nuclear factor kappaB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation. J Thorac Cardiovasc Surg 2002, 123:310-317. 10.1067/mtc.2002.118684, 11828291.
17. Ko JK, Choi KH, Kim HJ, Choi HY, Yeo DJ, Park SO, Yang WS, Kim YN, Kim CW. Conversion of Bfl-1, an anti-apoptotic Bcl-2 family protein, to a potent pro-apoptotic protein by fusion with green fluorescent protein (GFP). FEBS Lett 2003, 551:29-36. 10.1016/S0014-5793(03)00872-X, 12965200.
18. Denlinger CE, Rundall BK, Keller MD, Jones DR. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 2004, 78:1207-1214. discussion 1207-1214, 10.1016/j.athoracsur.2004.04.029, 15464472.
19. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 2008, 14:8143-8151. 10.1158/1078-0432.CCR-08-1539, 19088029.
20. Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H, Ungefroren H. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 2004, 109:182-188. 10.1002/ijc.11679, 14750167.
21. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 1999, 6:279-285. 10.1007/s10434-999-0279-x, 10340887.
22. Hopkins-Donaldson S, Cathomas R, Simoes-Wust AP, Kurtz S, Belyanskaya L, Stahel RA, Zangemeister-Wittke U. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int J Cancer 2003, 106:160-166. 10.1002/ijc.11209, 12800189.
23. Kim JK, Kim KD, Lee E, Lim JS, Cho HJ, Yoon HK, Cho MY, Baek KE, Park YP, Paik SG, et al. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line. Cancer Lett 2004, 212:61-70. 10.1016/j.canlet.2004.02.021, 15246562.
24. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999, 13:382-387. 10.1101/gad.13.4.382, 316475, 10049353.
25. Brien G, Trescol-Biemont MC, Bonnefoy-Berard N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene 2007, 26:5828-5832. 10.1038/sj.onc.1210363, 17353899.
26. Wang CY, Guttridge DC, Mayo MW, Baldwin AS. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999, 19:5923-5929. 84448, 10454539.
27. Kucharczak JF, Simmons MJ, Duckett CS, Gelinas C. Constitutive proteasome-mediated turnover of Bfl-1/A1 and its processing in response to TNF receptor activation in FL5.12 pro-B cells convert it into a prodeath factor. Cell Death Differ 2005, 12:1225-1239. 10.1038/sj.cdd.4401684, 16094403.
28. Ko JK, Lee MJ, Cho SH, Cho JA, Lee BY, Koh JS, Lee SS, Shim YH, Kim CW. Bfl-1S, a novel alternative splice variant of Bfl-1, localizes in the nucleus via its C-terminus and prevents cell death. Oncogene 2003, 22:2457-2465. 10.1038/sj.onc.1206274, 12717423.
29. Yang WS, Ko JK, Park SO, Choi HY, Kim YN, Kim CW. C-terminal region of Bfl-1 induces cell death that accompanies caspase activation when fused with GFP. J Cell Biochem 2005, 94:1234-1247. 10.1002/jcb.20381, 15696550.
30. Kim E, Kim JH, Shin HY, Lee H, Yang JM, Kim J, Sohn JH, Kim H, Yun CO. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003, 14:1415-1428. 10.1089/104303403769211637, 14577922.
31. Triezenberg SJ, LaMarco KL, McKnight SL. Evidence of DNA: protein interactions that mediate HSV-1 immediate early gene activation by VP16. Genes Dev 1988, 2:730-742. 10.1101/gad.2.6.730, 2843426.
32. Triezenberg SJ, Kingsbury RC, McKnight SL. Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression. Genes Dev 1988, 2:718-729. 10.1101/gad.2.6.718, 2843425.
33. Waterhouse NJ, Trapani JA. A new quantitative assay for cytochrome c release in apoptotic cells. Cell Death Differ 2003, 10:853-855. 10.1038/sj.cdd.4401263, 12815469.
34. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001, 7:3269-3275.
35. Rieger J, Durka S, Streffer J, Dichgans J, Weller M. Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. Eur J Pharmacol 1999, 365:301-308. 10.1016/S0014-2999(98)00883-8, 9988115.
36. Cheng Q, Lee HH, Li Y, Parks TP, Cheng G. Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene 2000, 19:4936-4940. 10.1038/sj.onc.1203861, 11039911.
37. Boland MP, Fitzgerald KA, O'Neill LA. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. The Journal of biological chemistry 2000, 275:25231-25238. 10.1074/jbc.275.33.25231, 10940316.
38. Santini V, Bernabei A, Gozzini A, Scappini B, Zoccolante A, D'Ippolito G, Figuccia M, Ferrini PR. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders. Haematologica 1997, 82:11-15.
39. Pace E, Melis M, Siena L, Bucchieri F, Vignola AM, Profita M, Gjomarkaj M, Bonsignore G. Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines. Cancer chemotherapy and pharmacology 2000, 46:467-476. 10.1007/s002800000183, 11138460.
40. Carmichael J. The role of gemcitabine in the treatment of other tumours. Br J Cancer 1998, 78(Suppl 3):21-25. 2062798, 9717987.
41. Takeuchi N, Maejima S, Hasebe O, Matsuda Y, Hanazaki K, Kajikawa S, Mukawa K, Hosokawa K, Hayashi K, Hisa T, et al. [Clinical problems in gemcitabine treatment for unresectable pancreatic cancer in the elderly--a multicentric retrospective study of 53 cases]. Gan To Kagaku Ryoho 2004, 31:1987-1991.
42. Sakamoto H, Kitano M, Suetomi Y, Takeyama Y, Ohyanagi H, Nakai T, Yasuda C, Kudo M. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J Gastroenterol 2006, 41:70-76. 10.1007/s00535-005-1724-7, 16501860.
43. Meng F, Henson R, Patel T. Chemotherapeutic stress selectively activates NF-kappa B-dependent AKT and VEGF expression in liver cancer-derived endothelial cells. Am J Physiol Cell Physiol 2007, 293:C749-760. 10.1152/ajpcell.00537.2006, 17537803.
44. Abratt RP, Sandler A, Crino L, Steward WP, Shepherd FA, Green MR, Nguyen B, Peters GJ. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Semin Oncol 1998, 25:35-43.
45. Arlt A, Schafer H. NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 2002, 40:336-347.
46. Ko JK, Choi KH, Peng J, He F, Zhang Z, Weisleder N, Lin J, Ma J. Amphipathic tail-anchoring peptide and Bcl-2 homology domain-3 (BH3) peptides from Bcl-2 family proteins induce apoptosis through different mechanisms. J Biol Chem 2011, 286:9038-9048. 10.1074/jbc.M110.198457, 21189256.
47. Werner AB, de Vries E, Tait SW, Bontjer I, Borst J. Bcl-2 family member Bfl-1/A1 sequesters truncated bid to inhibit is collaboration with pro-apoptotic Bak or Bax. J Biol Chem 2002, 277:22781-22788. 10.1074/jbc.M201469200, 11929871.
48. Ko JK, Choi KH, Pan Z, Lin P, Weisleder N, Kim CW, Ma J. The tail-anchoring domain of Bfl1 and HCCS1 targets mitochondrial membrane permeability to induce apoptosis. J Cell Sci 2007, 120:2912-2923. 10.1242/jcs.006197, 17666431.